

AD _____

GRANT NUMBER DAMD17-94-J-4339

TITLE: A Genetic Approach to Identifying Signal Transduction
Mechanisms Initiated by Receptors for TGF-B-Related Factors

PRINCIPAL INVESTIGATOR: F. Michael Hoffmann, Ph.D.

CONTRACTING ORGANIZATION: University of Wisconsin
Madison, Wisconsin 53706-4880

REPORT DATE: October 1996

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved

OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1996	3. REPORT TYPE AND DATES COVERED Annual (1 Oct 95 - 30 Sep 96)	
4. TITLE AND SUBTITLE A Genetic Approach to Identifying Signal Transduction Mechanisms Initiated by Receptors for TGF-Beta-Related Factors			5. FUNDING NUMBERS DAMD17-94-J-4339	
6. AUTHOR(S) F. Michael Hoffmann, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Wisconsin Madison, Wisconsin 53706-4880			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, MD 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE DTIC QUALITY INSPECTED 2	
13. ABSTRACT (Maximum 200) A genetic screen for new mutations affecting the signaling pathway by which cells respond to TGF- β -related factors in Drosophila was carried out. The genetic background was sensitized using a mutation in the Type I receptor gene. New mutations affecting the phenotypes caused by the sensitized genetic backgrounds were recovered. The new mutations were mapped to six different genes. Three of these genes were previously shown to participate in the signaling pathway, confirming that the sensitized genetic background was appropriate. DNA sequencing is being used to confirm the generation of new mutant alleles in the Mad gene and the Type II receptor gene. Three of the genes in which new mutations were recovered map to regions not previously known to be involved in dpp signaling. Detailed genetic mapping has provided cloning strategies for the molecular identification of two of these genes.				
14. SUBJECT TERMS Breast Cancer Transforming growth factor beta; Genetics; Signal transduction; Drosophila; mutations			15. NUMBER OF PAGES 7	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

19970228 091

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

JMH Where copyrighted material is quoted, permission has been obtained to use such material.

JMH Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

JMH Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

JMH In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

JMH In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

JMH In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

JMH In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

J. Michael Hoff 10/28/96
PI - Signature Date

TABLE OF CONTENTS

Introduction	Page 2
Results	Page 2
Conclusions	Page 3
References	Page 4

INTRODUCTION:

The TGF- β growth and differentiation factors have been implicated in the regulation of breast epithelial cell proliferation and in the invasive behavior of metastatic breast cancer (for example: Pierce et al., 1995). The goal of our research is to identify the molecules involved in the signal transduction cascades activated by TGF- β . Defects in the type II TGF- β receptor are associated with different human tumors (for example: Markowitz, S. et al., 1995). Recently the Mad proteins have been implicated as proteins on the TGF- β signaling pathway (Zhang et al., 1996). Mutations in the Mad proteins Madr2 and Dpc4 have been reported in colon and pancreatic carcinomas (Eppert et al., 1996; Hahn et al., 1996). We predict that other, currently unknown, molecules in the signaling cascades may also be affected during tumor progression.

In order to apply a genetic approach to the dissection of this signaling pathway, we have proposed to use the TGF- β -related genes and related receptor genes in the fruit fly *Drosophila*. Because of the high degree of evolutionary conservation, we predict that the *Drosophila* genes identified in our screens will provide the necessary molecular probes for the identification of the homologous genes in the human genome. This working hypothesis has been confirmed by work on Mad, a gene identified by genetic methods in *Drosophila* (Sekelsky et al., 1995) that was used to identify human homologs Madr1- Madr4 (Zhang et al., 1996).

RESULTS:

We characterized mutations in the *Drosophila* gene thickveins, which encodes a type I receptor essential for signaling by the TGF- β -related *Drosophila* ligand, dpp. Over the past year we have determined that a mutation in thick veins gene (tkv6) sensitizes the genetic background such that mutations in other known genes of the dpp signaling pathway cause detectable phenotypes. In this genetic background, recessive loss-of-function mutations in the *Drosophila* type II receptor punt or in the Mad gene have a dominant phenotypic effect. We concluded that in the tkv6 genetic background, other genes on the pathway become dosage-sensitive such that a reduction in the wildtype copy number from two to one causes a detectable phenotype. In this case, the phenotypes detected

include changes on the adult cuticle such as loss of distal structures from the legs and defects in the fusion of the dorsal notum.

Over the past year we screened 10,000 mutagenized chromosomes in an F2 screen for second site modifier mutations that enhanced the *tkv6* phenotype. We recovered and placed into stock 14 mutations. These mutations have been mapped by several criteria. They were tested for their ability to complement mutations in known genes on the pathway. Importantly, five of the mutations failed to complement mutations in *Mad*, two failed to complement mutations in *punt* and one failed to complement mutations in *Medea*. The recovery of new alleles in three genes known to be on the pathway confirmed the appropriateness of the genetic background and the screening procedures. We are currently sequencing the new alleles of *Mad* and *punt* to provide molecular characterization of these alleles.

The other six mutations are being mapped by meiotic recombination and complementation tests with known deletions. They identify three different complementation groups with one, one and four alleles in each. Because these mutations were generated with the chemical mutagen ethylnitrososurea which causes single base changes, we have screened for gamma-ray induced recessive lethals in each of the three complementation groups. These F2 lethal screens successfully identified new alleles in two of the complementation groups for which we had only single alleles. Gamma rays were used in an effort to produce chromosome rearrangements that would help in locating the position of the gene and provide a lesion detectable on Southern blots during the cloning strategies. We are currently in the process of trying to clone two of these three new loci.

CONCLUSIONS:

We have successfully carried out a medium scale mutagenesis for genetic modifiers in the signaling pathway of the TGF-beta-related *dpp* protein in *Drosophila*. Recovery of new alleles of *Mad* and the type II *punt* receptor indicate the screen was successful. Mutations identifying three other, potentially novel genes have been recovered and characterized. Molecular cloning strategies for two of these genes have been identified and are in progress. This is consistent with the goals and time table initially proposed. We are

also continuing our genetic screens in order to generate additional modifier mutations.

In summary, our progress thus far is on track with the Statement of Work (Appendix G, pg. 23) of our original proposal. We have made good progress in the first 24 months on Task #1 and #2 and are beginning Task #3 on schedule.

REFERENCES

- Eppert, K. et al., (1996) MADR2 maps to 18q21 and encodes a TGF- β -regulated MAD-related protein that is functionally mutated in colorectal carcinoma. *Cell* 86: 543-552.
- Hahn, S.A. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* 271: 350-353.
- Markowitz, S. et al., (1995) Inactivation of the type II TGF- β receptor in colon cancer cells with microsatellite instability. *Science* 268: 1336-1338.
- Pierce, D.F. et al., (1995) Mammary tumor suppression by transforming growth factor β 1 transgene expression. *PNAS* 92: 4254-4258.
- Sekelsky, J.J. et al., (1995) Genetic characterization and cloning of *Mothers against dpp*, a gene required for *decapentaplegic* function in *Drosophila melanogaster*. *Genetics* 139: 1347-1358.
- Zhang, Y., X-H. Feng, R-Y. Wu and R. Derynck (1996) Receptor-associated Mad homologues synergize as effectors of the TGF- β response. *Nature* 383: 168-172.